ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

In 15% to 30% of patients with acute myeloid leukemia (AML), aberrant proliferation is a consequence of a juxtamembrane mutation in the FLT3 gene (FMS-like tyrosine kinase 3–internal tandem duplication [FLT3-ITD]), causing constitutive kinase activity. ABT-869 (a multitargeted receptor tyrosine kina...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shankar, Deepa B., Li, Junling, Tapang, Paul, Owen McCall, J., Pease, Lori J., Dai, Yujia, Wei, Ru-Qi, Albert, Daniel H., Bouska, Jennifer J., Osterling, Donald J., Guo, Jun, Marcotte, Patrick A., Johnson, Eric F., Soni, Niru, Hartandi, Kresna, Michaelides, Michael R., Davidsen, Steven K., Priceman, Saul J., Chang, Jenny C., Rhodes, Katrin, Shah, Neil, Moore, Theodore B., Sakamoto, Kathleen M., Glaser, Keith B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2007
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1852258/
https://ncbi.nlm.nih.gov/pubmed/17209055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-029579
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados